MUSTANG BIO, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MUSTANG BIO, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $0 | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | $0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | $0 | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | $0 | Mar 16, 2020 |
| FY2019 | Dec 31, 2018 | ($50.0K) | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | $0 | Mar 16, 2020 |
| FY2019 | Jun 30, 2018 | $0 | Mar 16, 2020 |
| FY2019 | Mar 31, 2018 | $50.0K | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $0 | Mar 18, 2019 |
| FY2018 | Sep 30, 2017 | $0 | Mar 18, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $0 | Mar 29, 2018 |
| FY2017 | Sep 30, 2017 | $0 | Mar 29, 2018 |
| FY2017 | Jun 30, 2017 | $0 | Mar 29, 2018 |
| FY2017 | Mar 31, 2017 | $0 | Mar 29, 2018 |
| FY2017 | Dec 31, 2016 | $0 | Mar 29, 2018 |
| FY2017 | Sep 30, 2016 | $0 | Mar 29, 2018 |
| FY2017 | Jun 30, 2016 | $0 | Mar 29, 2018 |
| FY2017 | Mar 31, 2016 | $0 | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | $0 | Mar 31, 2017 |
| FY2016 | Sep 30, 2015 | $0 | Mar 31, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.92M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($15.75M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($51.60M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($77.53M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($66.37M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($60.02M) | Mar 23, 2022 |
| FY2019 | Dec 31, 2019 | ($16.21M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($10.17M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($10.40M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($9.61M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.43M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($16.25M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($49.26M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($76.16M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($66.72M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($56.81M) | Mar 23, 2022 |
| FY2019 | Dec 31, 2019 | ($15.92M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2019 | ($10.00M) | Mar 16, 2020 |
| FY2019 | Jun 30, 2019 | ($10.21M) | Mar 16, 2020 |
| FY2019 | Mar 31, 2019 | ($9.75M) | Mar 16, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $2.10M | Mar 18, 2019 |
| FY2017 | Dec 31, 2017 | $100.0K | Mar 29, 2018 |
| FY2016 | Dec 31, 2016 | $2.00M | Mar 31, 2017 |
| FY2016 | Dec 31, 2015 | $1.50M | Mar 31, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.26M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($11.41M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($49.48M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($65.07M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($53.67M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($37.32M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($33.58M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($19.24M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($12.95M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($4.13M) | Mar 29, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $0 | Mar 28, 2025 |
| FY2024 | Dec 31, 2023 | $64.0K | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $2.71M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $3.99M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $1.93M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $2.35M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $6.87M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $424.0K | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.59M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $9.31M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $17.74M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $92.42M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $125.17M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $109.90M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $73.45M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $42.75M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $63.49M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $27.50M | Mar 29, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.06M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $13.18M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $17.62M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $46.15M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $12.77M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.47M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $21.79M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $6.36M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $3.66M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $3.22M | Mar 29, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.53M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($3.87M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2023 | $123.0K | Mar 19, 2026 |
| FY2024 | Dec 31, 2022 | $46.27M | Mar 28, 2025 |
| FY2023 | Dec 31, 2021 | $112.40M | Mar 11, 2024 |
| FY2022 | Dec 31, 2020 | $98.44M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $51.65M | Mar 23, 2022 |
| FY2020 | Dec 31, 2018 | $36.40M | Mar 24, 2021 |
| FY2019 | Dec 31, 2017 | $59.83M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $24.28M | Mar 18, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($398.64M) | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | ($396.72M) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | ($380.97M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($329.37M) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | ($251.84M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($185.47M) | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | ($125.46M) | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | ($79.07M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($48.41M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($17.12M) | Mar 29, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.27M | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | $6.84M | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | $6.23M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $75.66M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $109.62M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $97.80M | Mar 23, 2022 |
| FY2020 | Dec 31, 2019 | $61.41M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | $16.47M | Mar 16, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (38) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (299) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 19, 2026 |
| FY2025 | Dec 31, 2024 | (38) | Mar 19, 2026 |
| FY2024 | Dec 31, 2023 | (299) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (10) | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 30, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | 70.92M | Mar 24, 2021 |
| FY2020 | Dec 31, 2019 | 39.40M | Mar 24, 2021 |
| FY2019 | Dec 31, 2018 | 26.61M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | 25.24M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 15.17M | Mar 29, 2018 |
| FY2016 | Dec 31, 2015 | 2.00M | Mar 31, 2017 |